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Abstract: Obstructive sleep apnea (OSA) is an important public health concern, which affects around 2–4% of
the population. Left untreated, it causes a decrease not only in quality of life, but also of life expectancy. Despite
the fact that knowledge about the mechanisms of development of cardiovascular disease in patients with OSA is
still incomplete, observations confirm a relationship between sleep disordered breathing and the rheological
properties of blood. One possible consequence of an increased incidence of cardiovascular disease may be a rise
in mortality in OSA patients. Continuously improved research methods are allowing for an increasingly more
accurate understanding of the significance of observed changes. (Folia Histochemica et Cytobiologica 2011, Vol.
49, No. 2, 206–210)
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Obstructive sleep apnea (OSA) is an important pub-
lic health concern. The estimated prevalence is 2%
in women and 4% in men [1]. It is characterized by
recurrent episodes of upper airway restriction during
sleep associated with an increased respiratory effort,
periodic arterial oxygen desaturations and sleep struc-
ture disorders. Daytime symptoms include an insa-
tiable sleepiness even after prolonged sleep, which
usually is not restorative.
According to the American Academy of Sleep
Medicine guidelines, obstructive sleep apnea can be
diagnosed when respiratory disturbance index (RDI)
is equal to or greater than 15, or when it is greater than
5 and accompanied by one of the typical symptoms
(pathological daytime sleepiness, restless sleep, fatigue
or insomnia, awakenings with a feeling of choking, ir-
regular snoring and/or pauses in breathing during sleep
observed by bed partners) [2]. Full overnight polysom-
nography remains the gold standard of OSA diagno-
sis. The first line of treatment in OSA patients without
significant comorbidities in the anatomy of their up-
per respiratory tract is the use of positive airway pres-
sure (CPAP, continuous positive air pressure).
Current knowledge regarding the natural history
of OSA is incomplete, but both the immediate and
the long-term consequences of untreated OSA are
undeniable [1, 3–6]. Circadian distribution of cardio-
vascular events including heart attacks and strokes
suggests an interaction between awakenings and acute
thrombosis.
It is believed that the increased incidence of vas-
cular events during the morning hours is linked in
some cases with coexisting OSA [5]. Such observa-
tions suggest the need for further research into the
role of sleep and associated disorders in the patho-
genesis of cardiovascular system diseases. Observa-
tions confirm a relationship between cardiovascular
incidents and sleep breathing disorders, both acute
(e.g. stroke, myocardial infarction, sudden death dur-
ing sleep) and chronic (e.g. hypertension, ischemic
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heart disease, heart failure) [1]. Due to the number
of common risk factors, this relationship cannot be
viewed as a simple cause and effect relationship.
The pathogenesis of cardiovascular disease in pa-
tients with sleep apnea syndrome undoubtedly de-
pends on several factors. One important association
between OSA and cardiovascular disease is excessive
sympathetic nervous system activity. Platelet aggre-
gation increase in patients with OSA may be second-
ary to the increased nocturnal levels of catechola-
mines. The elimination of apnea incidents via CPAP
therapy reduces platelet aggregation in conjunction
with nocturnal levels of catecholamines. Along with
the prevailing sympathetic activation, endothelial dys-
function has been reported as one cause of cardio-
vascular disease. Hypoxia, hypercapnia, and blood
pressure increases associated with OSA are elements
of endothelial function impairment. Increased levels
of endothelines may contribute to vasoconstriction
and other changes in the cardiovascular system.
Episodes of hypoxia followed by re-oxygenation
occur consecutively many times during the night over
many years in patients with untreated severe OSA,
and this leads to oxidative stress. The combination of
hypoxemia and sleep deprivation found in patients
with OSA also increases levels of inflammatory mark-
ers [1, 7]. Increased blood clotting, caused by chang-
es in the rheological properties of blood and plasma
[1, 3], seems to be an important factor linking OSA
and cardiovascular complications.
Understanding the physical phenomena associat-
ed with blood flow has been the subject of many re-
cent studies [5, 8–12]. The field of science devoted to
the analysis of these phenomena is called hemorhe-
ology. Evaluation of the rheological properties of
blood is based on measuring the viscosity of whole
blood and plasma and determining erythrocytes ag-
gregation and deformation abilities. Viscosity (viscos-
ity coefficient) is a measure of the resistance of the
liquids with mutual displacement of the fluid layers.
It is determined by the ratio of shear stress to shear
rate. Tangential stress g is defined as the ratio of tan-
gential force to the surface of the layers of flowing
liquid. Shear rate g is the velocity gradient between
the layers of the liquid [8]. At constant temperature
and pressure, the viscosity of Newtonian fluids also
remains constant, whereas in the case of non-Newto-
nian fluids it is a function of shear rate. Whole blood
viscosity measurements are carried out using capil-
lary rheometers or plasma-rotational rheometers,
which also allow the measurement of plasma viscosi-
ty. The ability of erythrocytes to aggregate is deter-
mined in aggregometers by measuring the scattered
light. Erythrocyte deformability is assessed on the
basis of flow time, either through the capillary or fil-
tration methods.
Blood is a liquid constituting a heterogeneous cell
suspension in the plasma. It is a typical non-Newto-
nian fluid of pseudo-plastic and thixotropic charac-
teristics with complex rheological properties. Liquids
in which viscosity decreases monotonically with the
increase of shear rate, are called ‘pseudo-plastic liq-
uids’. Non-Newtonian liquids, where viscosity depends
not only on shear rate, but also on the time and man-
ner of shearing, are called ‘thixotropic liquids’ [9].
Thixotropic properties are associated with the forma-
tion of structures in the absence of shear, and break-
downs in the presence of shear stress [9]. The main
factors determining the viscosity of blood are tem-
perature, vessel cross-section and shear rate factors
such as hematocrit, plasma viscosity, erythrocyte ag-
gregation and deformability [5], and the activity of
platelets. Hematocrit and plasma viscosity are so-
called ‘macro rheological’ factors, whereas deform-
ability and aggregation are called ‘micro rheological’
factors (Figure 1). The pathogenetic role of these fac-
tors varies. The relationship between hematocrit and
viscosity is non-linear. The effect of the plasma on
the viscosity of the blood is complex, and is both di-
rect and indirect [13]. The indirect effect is associat-
ed with the presence of fibrinogen and a2-globulin.
The direct effect is related to the flow of the erythro-
cytes suspended in plasma adjacent to the vascular
endothelium in narrow capillaries. The increase in
plasma viscosity impedes the flow, and thus deterio-
rates tissue perfusion [10]. Increased plasma viscosi-
ty also plays an important role in platelet adhesion to
the vascular endothelium. At constant hematocrit and
low shear rates, increased erythrocyte aggregation is
a major factor affecting blood viscosity, whereas at
high shear rates the major factor is a reduced deform-
ability [9]. Erythrocyte aggregation plays a significant
role in parts of the circulatory system, where blood
flow velocity gradients are reduced.
Figure 1. Determinants of blood viscosity at stable
temperature
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Blood viscosity is also determined by the mechan-
ical properties of red blood cells, mainly their de-
formability. It involves a special ability of shape shift-
ing of the red blood cells while maintaining an un-
changed volume. Such properties are of particular
importance during flow of the erythrocytes in the
capillaries, the diameter of which is smaller than that
of the red blood cells.
Although many papers on OSA and its traditional
cardiovascular risk factors have been published, few
publications have taken into account the role of blood
coagulation [2] and its influence on the rheological
properties of blood [14–19]. The limited number of
publications and methodological differences among
studies that describe the rheological properties of
blood hinder their comparative analysis. Lack of con-
sistent definitions for the diagnosis of sleep apnea is
also a limiting factor. The pioneering work of Chin et
al. [14] confirmed in 11 patients increased levels of
fibrinogen, hematocrit and indirectly blood viscosity
in the morning. An AHI of 20 (20 apnea/hypopnea
episodes per hour) and the presence of clinical symp-
toms were used as study inclusion criteria.
Nobili et al. [15] showed that blood viscosity in-
creased in the mornings in a group of 12 patients with
OSAS, but not in a group of eight healthy controls.
The criterion for diagnosis was respiratory distress
index > 5/h confirmed by a polysomnography study
and the presence of clinical symptoms.
Reinhard et al. [16] described the impact of six-month
CPAP therapy on a group of 13 patients with OSA com-
pared to eight healthy controls. They found that morn-
ing plasma viscosity was higher in patients with OSA.
Fibrinogen levels showed a correlation with plasma vis-
cosity. They also confirmed that blood viscosity and
platelet activity in patients treated with CPAP was com-
parable to healthy controls, and that a single night with-
out using a CPAP device had no significant effect on
examined blood parameters.
Zhang et al. [17] evaluated the biochemical char-
acteristics of a prothrombotic state in a group of 41
elderly patients (mean age 63.4 ± 4 years) with poly-
somnographically diagnosed sleep apnea syndrome
on the basis of AHI ≥ 5/h before and after 30-day
CPAP therapy, and compared the results to those of
healthy controls matched for age. They confirmed
a statistically significant increase, in the group with OSA,
of hematocrit, blood viscosity and platelet aggregation.
The 30-day CPAP therapy resulted in morning reduc-
tion of hematocrit, total blood viscosity, platelet ag-
gregation and prolongation of the prothrombin time
and activated partial thromboplastin time.
Tażbirek et al. [18] found an increase in blood vis-
cosity, corrected blood viscosity, plasma viscosity and
erythrocyte aggregation in obese men with polysom-
nographically confirmed OSA (AHI 45 with an aver-
age rate of 16.2 episodes per hour) as compared to
patients without OSA, matched in terms of age, BMI
and the incidence of coexisting diseases. They showed
that there was a correlation between the values of
measured parameters before the start of CPAP ther-
apy (blood viscosity, corrected blood viscosity, plas-
ma viscosity, aggregation index) in patients with OSA
and the polysomnographic severity indicators of OSA
(apnea-hypopnea index, SaO2 min, SaO2 < 90%).
The primary determinant of blood viscosity is the
viscosity of plasma. Increased viscosity affects the fric-
tional forces that inhibit the movement of erythro-
cytes; it positively correlates with total cholesterol [21],
low-density lipoproteins (LDL) and triglycerides
[19, 22]. Also, correlations between increased levels
of fibrinogen and plasma viscosity in obese patients
[23], as well as between fibrinogen and ischemic heart
disease, have been confirmed [24].
Wessendorf et al. [20] showed that elevated plas-
ma fibrinogen levels in stroke patients are accompa-
nied by a higher incidence of OSA. Their data con-
firmed a positive correlation between the plasma fi-
brinogen concentration and the number and duration
of recorded breathing disorders during sleep, and
a negative correlation with minimum and average blood
saturation. The authors suggest that high concentra-
tions of fibrinogen may lead to an increased incidence
of vascular disease in OSA.
Dikmenoglu et al. [5] compared the rheological
properties of blood in 11 patients with severe sleep
apnea syndrome to a control group matched for age
and gender. They found that plasma viscosity in pa-
tients with severe OSA was significantly higher. Morn-
ing blood viscosity showed a negative correlation with
the average and minimum saturation levels, and
a positive correlation with time spent in hypoxia (SaO2 <
< 90%) [5]. Elevated levels of proteins, including bio-
chemical markers of inflammation, are indicated as
a possible mechanism of increased plasma viscosity in
patients with OSA. A relationship between sleep dis-
ordered breathing and increased levels of CRP and
IL6 has been confirmed, as well as a correlation with
the severity of OSA [25–27]. Treatment with CPAP,
according to some authors, influences the decrease
of these markers [25] although other researchers have
cast doubt on that dependency [28, 29]. It seems that
an important element linking inflammation with vas-
cular damage and sleep disordered breathing is the
phenomenon of periodic hypoxia followed by re-oxy-
genation. Dikmenoglu et al. [5] described increased
morning levels of plasma malondialdehyde (malon-
dialdehyde-MDA) in a group of patients with severe
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OSA. Malondialdehyde is a product of per-oxidation
of polyunsaturated fatty acids and is one of the indi-
cators of oxidative stress, which affects the proper-
ties of plasma proteins. Also, in an earlier study by
Polish researchers [18], the increase in plasma vis-
cosity in the group with OSA compared to controls
was confirmed in the absence of statistically signifi-
cant differences in the total level of proteins, CRP
and fibrinogen. An increase of the aggregation index
in the group with OSA [18] suggests that another pos-
sible explanation of the cause of increased plasma vis-
cosity, which affects the ability of the erythrocytes to
aggregate, may be the change of the connections
among the proteins in plasma.
Aggregation is a complex phenomenon, which aris-
es from the combined effects of both the cell mem-
brane of erythrocytes (the electric charge, the vis-
coelastic properties of the cell membrane) and plas-
ma factors. Plasma factors which specifically increase
erythrocyte aggregation are known as ‘bridging pro-
teins’. Examples are fibrinogen, and 2-globulin and
immunoglobulins.
Increased erythrocyte aggregation ability within
a short period, and the statistically significant effects
of just five days of CPAP therapy on the parameters
of erythrocyte aggregation, point to the important
contribution of erythrocyte aggregation on the rheo-
logical properties of blood in patients with OSA [18].
Significant correlations between aggregation param-
eters (aggregation index, time T 1/2) and the param-
eters describing polysomnographic severity (time
spent in hypoxia-SaO2 < 90%, index of apnea and
hypopnea counts breathing-AHI and the apnea
length) confirm this relationship.
Deformability of erythrocytes is yet another im-
portant factor in blood viscosity: a reduction in
deformability increases blood viscosity [11, 30]. In
the phenomenon of deformation, it is primarily
the cell membrane and cytoskeleton proteins that
are involved.
Increased activity of antioxidant enzymes, which
is observed in patients with OSA, supports the inten-
sification of per-oxidation. Malondialdehyde (MDA),
which is the product of per-oxidation, modifies the
physical properties of cell membranes, causing dis-
ruptions in the hydrophobicity of the lipid interior
and the violation of the bilayer membrane structure
[31]. Lipid per-oxidation and its by-products cause
polymerization of membrane components and lead
to an increase in the stiffness of the phospholipid bi-
layer [32]. Yet there has been no unequivocal data on
impaired erythrocyte deformability as the main mech-
anism of increased blood viscosity. Previous studies
[5, 18] show only a statistically insignificant difference
between patients with OSA and controls. Failure to
find the impact of a five-day CPAP therapy [18] on the
test indicators of deformability justifies the need for
future assessment of the impact of long-term therapy.
One key rheological property of blood is the plate-
let function. Published studies have shown that plate-
let aggregation is increased in patients with OSA and
may be secondary to the increased levels of catechola-
mines during the night [1]. The release of catechola-
mines which accompanies awakenings [32] may con-
tribute to the change of rheological properties. De-
crease of the number of apnea and hypopnea episodes
to the level of physiological breathing with the aid of
CPAP reduces the ability of platelet aggregation in
conjunction with the change in levels of catechola-
mines [33, 34].
Hui et al. [35] confirmed increased platelet acti-
vation in a study of 42 patients with OSA (AHI > 10/
/hr.) compared to a control group of healthy subjects
matched for body weight. Platelet activation in that
study correlated with the rate of awakenings. CPAP
treatment reduced the activity of platelets, suggest-
ing that it may have a cardioprotective effect.
Although knowledge about the mechanisms of
development of cardiovascular disease in patients with
OSAS is still incomplete, current observations con-
firm   a relationship between sleep disordered breath-
ing and changes in the rheological properties of blood.
The concomitant increase in the frequency of cardio-
vascular disease observed in this group may be a con-
sequence of such changes. Continuously improved
research methods are allowing for an increasingly
more accurate understanding of the significance of
observed changes.
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